-
1.发明申请公开(公告)号：US20210220405A1
公开(公告)日：2021-07-22
申请号：US17198505
申请日：2021-03-11
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
2.发明申请公开(公告)号：US20190216854A1
公开(公告)日：2019-07-18
申请号：US16361438
申请日：2019-03-22
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
CPC classification number: A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
3.发明申请公开(公告)号：US20180021379A1
公开(公告)日：2018-01-25
申请号：US15711289
申请日：2017-09-21
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C07K14/725 , C12N5/0783 , C07K14/705 , C07K16/28 , A61K38/00
CPC classification number: A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
4.发明公开公开(公告)号：US20240309397A1
公开(公告)日：2024-09-19
申请号：US18530878
申请日：2023-12-06
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C12N15/85 , A61K35/17 , A61K38/00 , A61K39/00 , C07K14/705 , C07K14/725 , C07K16/28 , C12N5/0783
CPC classification number: C12N15/85 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C12N5/0636 , A61K38/00 , A61K39/00 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppresive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular, TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection. of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
5.发明申请公开(公告)号：US20220177914A1
公开(公告)日：2022-06-09
申请号：US17674436
申请日：2022-02-17
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C12N15/85 , A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20190216853A1
公开(公告)日：2019-07-18
申请号：US16361370
申请日：2019-03-22
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
7.发明申请公开(公告)号：US20170360835A1
公开(公告)日：2017-12-21
申请号：US15659792
申请日：2017-07-26
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K16/28 , C12N5/0783 , C07K14/725 , C07K14/705 , A61K38/00
CPC classification number: A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
8.发明申请公开(公告)号：US20220348955A1
公开(公告)日：2022-11-03
申请号：US17848590
申请日：2022-06-24
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: C12N15/85 , A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
9.发明申请公开(公告)号：US20200281979A1
公开(公告)日：2020-09-10
申请号：US16876079
申请日：2020-05-17
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
10.发明申请公开(公告)号：US20180360883A1
公开(公告)日：2018-12-20
申请号：US16027629
申请日：2018-07-05
Applicant: Cellectis
Inventor： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC: A61K35/17 , C07K14/705 , C12N5/0783 , C07K16/28 , C07K14/725
Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.013 seconds)
